To determine if modulating expression of VPS4A by knocking down expression in CRC cell line could improve sensitivity to agents usually used in the treatment of CRC, Oxa, 5-FU, and Iri, the SW480/shVPS4A and KM12/shVPS4A knockdown sublines were treated with each agent and response compared to treatment of the SW480/shSCR and KM12/shSCR control sublines, respectively, using an MTT cytotoxicity assay. This evidence concerns the gene VPS4A and colorectal carcinoma.